PCMA To Promote More Comparative Effectiveness Analysis
This article was originally published in The Pink Sheet Daily
Executive Summary
Trade group welcomes greater scrutiny of drugs' effectiveness, but emphasizes that decisions should remain in the hands of PBMs.
You may also be interested in...
Statin Savings: New Generic Options Could Boost Brand Switches, Cut Costs For Medicare
Introduction of new, more effective generic statins could yield $8.2 bil. for Medicare benefit in 2007, Consumers Union report says.
‘Shadow’ Factory Challenges Continue For US FDA
Agency wants more information about API suppliers as it winds up case against KV Tech for hidden use of Dr. Reddy’s plant and seeks to find disappearing manufacturer of contaminated OTC eye drops.
US FDA, USP Raise Questions About Valisure’s Assertions Of Benzoyl Peroxide’s Benzene Risks
The US drug regulatory authority and standard-setting organization are evaluating the drug-screening venture’s findings regarding stability and potential carcinogenic risks associated with the widely used acne treatment, which includes Rx formulations.